Cerezuela-Fuentes, PabloGonzalez-Cao, MariaPuertolas, TeresaManzano, Jose LuisMaldonado, CayetanaYelamos, OriolBerciano-Guerrero, Miguel AMartin-Liberal, JuanMuñoz-Couselo, EvaEspinosa, EnriqueDrozdowskyj, AnaBerrocal, AlfonsoSoria, AinaraMarquez-Rodas, IvanMartin-Algarra, SalvadorQuindos, MariaPuig, Susana2025-05-282025-05-282024-07-01Cerezuela-Fuentes P, Gonzalez-Cao M, Puertolas T, Manzano JL, Maldonado C, Yelamos O, et al. Access to systemic treatment of non-melanoma skin cancer in Spain: a survey analysis. Clin Transl Oncol. 2025 Jan;27(1):386-3911699-048Xhttps://hdl.handle.net/10668/28505Background Novel and highly efective drugs for non-melanoma skin cancer (NMSC) improve patient outcomes, but their high cost strains healthcare systems. Spain’s decentralized public health system, managed by 17 autonomous communities (AaCc), raises concerns about equitable access. Methods A cross-sectional survey (July–September 2023) was sent to Spanish Multidisciplinary Melanoma Group (GEM Group) members to assess access to new drugs. Findings Fifty physicians from 15 Spanish AaCc responded to the survey. Access for drug with approved public reimbursement, Hedgehog inhibitors in basal-cell carcinoma and anti PD-L1 antibody in Merkel carcinoma, was observed in 84% and 86% of centers, respectively. For other EMA-approved treatments, but without reimbursement in Spain access decreased to 78% of centers. Heterogeneity in access was mainly observed intra regions. Conclusion Unequal fnancial support for drugs for NMSC with creates a patchwork of access across Spanish hospitals, with variations even within the same AaCc.enAccessInnovative therapiesNon-melanoma skin cancerCross-Sectional StudiesPublic HealthAntineoplastic AgentsCarcinoma, Basal CellSkin NeoplasmsPhysiciansDelivery of Health Careresearch article38951438restricted accessEspañaCarcinomaEsguinces y distensionesSalud públicaCostos y análisis de costoNeoplasias Cutáneas10.1007/s12094-024-03583-5